A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design

Marie Jauffret-Roustide, Yann Le Strat, Elisabeth Couturier, Damien Thierry, Marc Rondy, Martine Quaglia, Nicolas Razafandratsima, Julien Emmanuelli, Gaelle Guibert, Francis Barin, Jean-Claude Desenclos, Marie Jauffret-Roustide, Yann Le Strat, Elisabeth Couturier, Damien Thierry, Marc Rondy, Martine Quaglia, Nicolas Razafandratsima, Julien Emmanuelli, Gaelle Guibert, Francis Barin, Jean-Claude Desenclos

Abstract

Background: Epidemiology of HCV infection among drug users (DUs) has been widely studied. Prevalence and sociobehavioural data among DUs are therefore available in most countries but no study has taken into account in the sampling weights one important aspect of the way of life of DUs, namely that they can use one or more specialized services during the study period. In 2004-2005, we conducted a national seroepidemiologic survey of DUs, based on a random sampling design using the Generalised Weight Share Method (GWSM) and on blood testing.

Methods: A cross-sectional multicenter survey was done among DUs having injected or snorted drugs at least once in their life. We conducted a two stage random survey of DUs selected to represent the diversity of drug use. The fact that DUs can use more than one structure during the study period has an impact on their inclusion probabilities. To calculate a correct sampling weight, we used the GWSM. A sociobehavioral questionnaire was administered by interviewers. Selected DUs were asked to self-collect a fingerprick blood sample on blotting paper.

Results: Of all DUs selected, 1462 (75%) accepted to participate. HCV seroprevalence was 59.8% [95% CI: 50.7-68.3]. Of DUs under 30 years, 28% were HCV seropositive. Of HCV-infected DUs, 27% were unaware of their status. In the month prior to interview, 13% of DUs shared a syringe, 38% other injection parapharnelia and 81% shared a crack pipe. In multivariate analysis, factors independently associated with HCV seropositivity were age over 30, HIV seropositivity, having ever injected drugs, opiate substitution treatment (OST), crack use, and precarious housing.

Conclusion: This is the first time that blood testing combined to GWSM is applied to a DUs population, which improve the estimate of HCV prevalence. HCV seroprevalence is high, indeed by the youngest DUs. And a large proportion of DUs are not aware of their status. Our multivariate analysis identifies risk factors such as crack consumption and unstable housing.

Figures

Figure 1
Figure 1
Observed links (arrows) and declared links (dotted arrows) between the population of services and the population of drug users, ANRS-Coquelicot study, France 2004–2005. The shaded boxes represent the sampled services and the sampled individuals.
Figure 2
Figure 2
HIV and HCV seroprevalence by age among French DUs, ANRS-Coquelicot study, France 2004–2005 (N = 817, DUs who consented to be tested).

References

    1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi: 10.1056/NEJM199908193410802.
    1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–39.
    1. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, Moss AR. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study) J Urban Health. 2003;80:137–146. doi: 10.1007/BF02416932.
    1. Prithwish DE, Roy E, Boivin JF, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic review. J Viral Hepat. 2008;15:279–92. doi: 10.1111/j.1365-2893.2007.00942.x.
    1. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS. 1996;10:311–317. doi: 10.1097/00002030-199603000-00010.
    1. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S25–S29.
    1. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42–46. doi: 10.2105/AJPH.91.9.1350.
    1. Mathei C, Shkedy Z, Denis B, Kabali C, Aerts M, Molenberghs G, Van Damme P, Buntinx F. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J Viral Hepat. 2006;13:560–570. doi: 10.1111/j.1365-2893.2006.00725.x.
    1. Zwahlen M, Vlahov D. Commentary: Modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users. Int J Epidemiol. 2003;32:715–716. doi: 10.1093/ije/dyg169.
    1. Murray JM, Law MG, Gao Z, Kaldor JM. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol. 2003;32:708–714. doi: 10.1093/ije/dyg102.
    1. Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, Schechter MT. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36:737–742. doi: 10.1053/jhep.2002.35065.
    1. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558–1564. doi: 10.1086/345554.
    1. Moore D, Fraser S. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications. Soc Sci Med. 2006;62:3035–3047. doi: 10.1016/j.socscimed.2005.11.067.
    1. Marlatt GA. Harm reduction: pragmatic strategies for managing high-risk behaviours. New York: Guilford Press; 1998.
    1. Kleinig J. Ethical issues in substance use intervention. Subst Use Misuse. 2004;39:369–398. doi: 10.1081/JA-120029983.
    1. Jauffret-Roustide M. Les drogues: approche sociologique, économique et politique. Paris: La Documentation Française; 2004.
    1. Des Jarlais DC, Friedman SR. Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep. 1998;113(Suppl 1):182–188.
    1. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274–3277.
    1. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr. 2003;33:356–364.
    1. Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, Burns S, Molyneaux P, McIntyre PG, Goldberg DJ. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect. 2007;135:433–442. doi: 10.1017/S0950268806007035.
    1. Mathei C, Buntinx F, Van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat. 2002;9:157–173. doi: 10.1046/j.1365-2893.2002.00339.x.
    1. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101:1499–1508. doi: 10.1111/j.1360-0443.2006.01543.x.
    1. Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R, Alter MJ. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 2006;44:341–351. doi: 10.1002/hep.21252.
    1. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, Rockwell R, Hoover D, Williams IT, Monterroso ER. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001;91:23–30. doi: 10.2105/AJPH.91.6.927.
    1. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis. 2005;40(Suppl 5):S330–S335. doi: 10.1086/427475.
    1. Crofts N, Jolley D, Kaldor J, Van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health. 1997;51:692–697. doi: 10.1136/jech.51.6.692.
    1. Bacchetti P, Tien PC, Seaberg EC, O'Brien TR, Augenbraun MH, Kral AH, Busch MP, Edlin BR. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis. 2007;7:145. doi: 10.1186/1471-2334-7-145.
    1. Coutinho RA. HIV and hepatitis C among injecting drug users. BMJ. 1998;317:424–425.
    1. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust. 1999;170:220–221.
    1. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157:467–471. doi: 10.1093/aje/kwf222.
    1. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction. 2005;100:1690–1700. doi: 10.1111/j.1360-0443.2005.01271.x.
    1. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence – a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004;81:20–24.
    1. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, Hall AJ. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ. 2005;330:24–25. doi: 10.1136/bmj.38286.841227.7C.
    1. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003;32:717–724. doi: 10.1093/ije/dyg101.
    1. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS. 2007;21:1967–1969. doi: 10.1097/QAD.0b013e3282ef7701.
    1. Jauffret-Roustide M, Emmanuelli J, Quaglia M, Barin F, Arduin P, Laporte A, Desenclos JC. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data – the ANRS-Coquelicot Study. Subst Use Misuse. 2006;41:1603–1621. doi: 10.1080/10826080600847951.
    1. Stern RK, Hagan H, Lelutiu-Weinberger C, Des Jarlais D, Scheinmann R, Strauss S, Pouget ER, Flom P. The HCV Synthesis Project: Scope, methodology, and preliminary results. BMC Med Res Methodol. 2008;8:62. doi: 10.1186/1471-2288-8-62.
    1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18:352–358. doi: 10.1016/j.drugpo.2007.04.004.
    1. Bello PY, Toufik A, Gandilhon M, Giraudon I. Phénomènes émergents liés aux drogues en 2004. Sixième rapport national du dispositif TREND. OFDT. Saint-Denis; 2005.
    1. Gadel G, Nunes C. Les toxicomanes suivis dans les structures sanitaires et sociales en novembre 1996. Etudes et Résultats. 1998;1:1–6.
    1. Ingold R. Etude multicentrique sur les attitudes et les comportements des toxicomanes face aux risques de contamination par le VIH et les virus de l'hépatite. IREP; 1996.
    1. Palle C, Tellier S. Les usagers de drogues illicites pris en charge par le système de soins en novembre 1997. Etudes et Résultats. 2000;59:1–8.
    1. Ardilly P, Le Blanc D. Sampling and weighting a survey of homeless persons: a French example. Survey Methodology. 2001;27:109–118.
    1. Lavallée P. Indirect sampling. New York: Springer; 2007.
    1. Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl 2):S67–S72.
    1. Stimson GV, Jones S, Chalmers C, Sullivan D. A short questionnaire (IRQ) to assess injecting risk behaviour. Addiction. 1998;93:337–347. doi: 10.1046/j.1360-0443.1998.9333373.x.
    1. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, Plantier JC, Bernillon P, Le Vu S, Pinget R, Desenclos JC. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis. 2007;196:377–383. doi: 10.1086/519387.
    1. Jauffret-Roustide M. Sciences sociales et épidémiologie: des approches méthodologiques qui se complètent, à propos de la question des pratiques à risque chez les usagers de drogues. Bull Epidemiol Hebd. 2006;2–3:21–23.
    1. Jauffret-Roustide M, Oudaya L, Rondy M, Kudawu Y, Le Strat Y, Couturier E, Emmanuelli J, Desenclos JC. Life trajectory and risk-taking among women drug users. Med Sci (Paris) 2008;24(Spec No 2):111–121.
    1. Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis. 2002;35:783–788. doi: 10.1086/342063.
    1. Fuller CM, Vlahov D, Latkin CA, Ompad DC, Celentano DD, Strathdee SA. Social circumstances of initiation of injection drug use and early shooting gallery attendance: implications for HIV intervention among adolescent and young adult injection drug users. J Acquir Immune Defic Syndr. 2003;32:86–93.
    1. Vidal-Trecan GM, Varescon-Pousson I, Gagniere B, Lessenot S, Madariaga E, Boissonnas A. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Interne (Paris) 2002;153:219–225.
    1. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661. doi: 10.2105/AJPH.86.5.655.
    1. Novelli LA, Sherman SG, Havens JR, Strathdee SA, Sapun M. Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users. Drug Alcohol Depend. 2005;77:303–309. doi: 10.1016/j.drugalcdep.2004.08.021.
    1. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006;6:93. doi: 10.1186/1471-2334-6-93.
    1. McMahon JM, Pouget ER, Tortu S. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis. 2007;195:1572–1581. doi: 10.1086/516785.
    1. Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ. 2001;165:557–560.
    1. Des Jarlais DC, Braine N, Friedmann P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav. 2007;11:78–84. doi: 10.1007/s10461-007-9227-6.
    1. Foley D. Single-room occupancy hotels: possible solutions and alternatives. Body Posit. 1998;11:35–39.
    1. Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Peterson J, Pilote L, Moss AR. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA. 1994;272:455–461. doi: 10.1001/jama.272.6.455.
    1. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003;35:455–460.
    1. Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007;195:1052–1061. doi: 10.1086/512081.
    1. Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS, Von Bargen JC, Serrano Y. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:87–92. doi: 10.1097/00042560-199609000-00012.
    1. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS. 2005;19(Suppl 3):S199–S207. doi: 10.1097/01.aids.0000192090.61753.d4.
    1. Porter J, Bonilla L. Crack users' cracked lips: an additional HIV risk factor. Am J Public Health. 1993;83:1490–1491. doi: 10.2105/AJPH.83.10.1490-a.
    1. Fitzgerald T, Lundgren L, Chassler D. Factors associated with HIV/AIDS high-risk behaviours among female injection drug users. AIDS Care. 2007;19:67–74. doi: 10.1080/09540120600731727.
    1. Leigh BC, Stall R. Substance use and risky sexual behavior for exposure to HIV. Issues in methodology, interpretation, and prevention. Am Psychol. 1993;48:1035–1045. doi: 10.1037/0003-066X.48.10.1035.
    1. MacRae R, Aalto E. Gendered power dynamics and HIV risk in drug-using sexual relationships. AIDS Care. 2000;12:505–515. doi: 10.1080/09540120050123909.
    1. Spittal PM, Craib KJ, Wood E, Laliberte N, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002;166:894–899.
    1. Berg CH van den, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22:183–193. doi: 10.1007/s10654-006-9089-7.
    1. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Fremaux D, Josse P, Emmanuelli J, Le Strat Y, Desenclos JC, Filoche B. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect. 2004;132:699–708. doi: 10.1017/S095026880400247X.
    1. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Suppl 3):S20–S25. doi: 10.1097/01.aids.0000192066.86410.8c.
    1. Wright NM, Tompkins CN. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J. 2006;3:27. doi: 10.1186/1477-7517-3-27.
    1. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction . 2007;102:1454–1462. doi: 10.1111/j.1360-0443.2007.01912.x.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren